-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Prostate cancer is the second most common cancer in men and the fifth leading cause of cancer death among men worldwide.
cancer relies on androgens to promote tumor progression, and hormone therapy, which consumes or blocks androgens, is the main treatment for prostate cancer.
although tumors are initially sensitive to drugs or surgical treatments that lower testosterone levels, disease progression is often fatal.
In the past five years, despite advances in the treatment of patients with metastatic prostate cancer (mCRPC), other treatment options are needed to improve clinical outcomes, especially in patients who have failed in existing treatments or have a precontinence.
ESSA Pharma, a clinically-stage pharmaceutical company dedicated to developing new treatments for prostate cancer, recently announced positive results from EPI-7386 preclinical data presented at the 2020 ESMO Virtual Conference.
EPI-7386 is a second-generation N-end domain androgen inhibition that, in the in-body VCaP model, combines EPI-7386 with enzalutamide, apalutamide, or daroamide to inhibit AR-related transcription activity more widely and deeply than using each single drug alone.
R. Parkinson, President and CEO of ESSA Pharma, said, "These data provide strong evidence for studying the effectiveness of EPI-7386 in treating prostate cancer."
.
